NCT03699176 - Assessment of Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids | Biotech Hunter

Timeline

Start Date

October 27, 2018

Primary Completion Date

December 25, 2019

Study Completion Date

December 25, 2019

Conditions

Uterine Fibroids

Interventions

DRUG

Vilaprisan (BAY1002670)

2 mg, once daily, oral

DRUG

Placebo

Once daily, oral

Trial Locations (8)

Funabashi Municipal Medical Center, Funabashi

Matsudo City General Hospital, Matsudo

Ena Odori Clinic, Sapporo

Tokeidai Memorial Clinic, Sapporo

Asahi clinic, Takamatsu

Kagawa Prefectural Central Hospital, Takamatsu

Unoki Clinic, Kagoshima

Japanese Red Cross Kumamoto Hospital, Kumamoto